新华制药(000756.SZ)获得磷酸奥司他韦干混悬剂药品注册证书

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Oseltamivir Phosphate Dry Suspension, which is indicated for the treatment of influenza A and B in patients aged 2 weeks and older [1] Group 1 - The product is effective for treating both influenza A and B, although clinical data for influenza B is limited [1] - Patients are advised to use the product within 48 hours of the onset of symptoms [1] - The product can also be used for the prevention of influenza A and B in individuals aged 1 year and older [1]